Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

References

• DalePRCerneckaHSchmidtMThe pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoceptor agonists in the treatment of airway and bladder diseaseCurr Opin Pharmacol201416314224682092
   PubMed Web of Science ®Google Scholar
• CohenJSMilesMCDonohueJFOharJADual therapy strategies for COPD: the scientific rationale for LAMA + LABAInt J Chron Obstruct Pulmon Dis20161178579727143870
   PubMed Web of Science ®Google Scholar
• Lopez-CamposJLM(2)-beta(2) interaction: a basis for combined bronchodilator treatmentArch Bronconeumol201349727928123122560
   PubMed Web of Science ®Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• MateraMGRoglianiPCalzettaLCazzolaMSafety considerations with dual bronchodilator therapy in COPD: an updateDrug Safety201639650150826924197
   PubMed Web of Science ®Google Scholar
• Lopez-CamposJLAbad-ArranzMCalero-AcunaCDouble or dual bronchodilation: defining the correct termArch Bronconeumol2015511266125910546
   PubMed Web of Science ®Google Scholar
• KalbergCO’DellDGalkinDNewlandsAFahyWADual bronchodilator therapy with umeclidinium/vilanterol versus tiotropium plus indacaterol in chronic obstructive pulmonary disease: a randomized controlled trialDrugs R D201616221722727028749
   PubMedGoogle Scholar
• HuismanELCockleSMIsmailaASKarabisAPunekarYSComparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysisInt J Chron Obstruct Pulmon Dis2015101863188126392761
   PubMed Web of Science ®Google Scholar
• ObaYSarvaSTDiasSEfficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysisThorax2016711152526490732
   PubMed Web of Science ®Google Scholar
• CalzettaLRoglianiPMateraMGCazzolaMA systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPDChest201614951181119626923629
   PubMed Web of Science ®Google Scholar
• SchlueterMGonzalez-RojasNBaldwinMGroenkeLVossFReasonTComparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysisTher Adv Respir Dis20161028910426746383
   PubMed Web of Science ®Google Scholar
• FarneHACatesCJLong-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201510CD008989
   Google Scholar
• MenziesDSystematic reviews and meta-analysesInt J Tuberc Lung Dis201115558259321756509
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
   PubMed Web of Science ®Google Scholar
• WatzHMailanderCBaierMKirstenAEffects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)BMC Pulm Med20161619527301417
   PubMed Web of Science ®Google Scholar
• D’UrzoADRennardSIKerwinEMEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res20141512325756831
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• BatemanEDChapmanKRSinghDAclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)Respir Res2015169226233481
   PubMed Web of Science ®Google Scholar
• SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• WilsonMRPatelJGColemanAMcDadeCLStanfordRHEarnshawSRCost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic modelInt J Chron Obstruct Pulmon Dis201712997100828392684
   PubMed Web of Science ®Google Scholar
• van BovenJFKocksJWPostmaMJCost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropiumolodaterol for patients with COPD in the NetherlandsInt J Chron Obstruct Pulmon Dis2016112191220127703341
   PubMed Web of Science ®Google Scholar
• RamosMHaughneyJHenryNLindnerLLamotteMCost versus utility of aclidinium bromide 400 microg plus formoterol fumarate dihydrate 12 microg compared to aclidinium bromide 400 microg alone in the management of moderate-to-severe COPDClinicoecon Outcomes Res2016844545627672337
   PubMed Web of Science ®Google Scholar
• PriceDKeiningerDCosta-ScharplatzMCost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare settingRespir Med2014108121786179325307414
   PubMed Web of Science ®Google Scholar
• TebbothATernouthAGonzalez-RojasNUK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPDClinicoecon Outcomes Res2016866767427853383
   PubMedGoogle Scholar
• MolimardMRaherisonCLignotSChronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patientsEur Respir J2017492160179428182569
   PubMed Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDMunzuCKilbrideSChurchAMagnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trialsRespir Med2016112657426797016
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• JonesPWEstimation and application of the minimum clinically important difference in COPDLancet Respir Med20142316716924621674
   PubMed Web of Science ®Google Scholar
• AgustiACalverleyPMCelliBCharacterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
   PubMed Web of Science ®Google Scholar
• HananiaNAFeldmanGZachgoWThe efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialChest2012142111912722241764
   PubMed Web of Science ®Google Scholar